Carregant...
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
PURPOSE: Etirinotecan pegol (EP), a long-acting topoisomerase-1 inhibitor, is a polyethylene glycol conjugate of irinotecan, with an intended indication for treatment of breast cancer with brain metastases. The objective of this study was to develop a population pharmacokinetic (popPK) model of EP a...
Guardat en:
| Publicat a: | Cancer Chemother Pharmacol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5907632/ https://ncbi.nlm.nih.gov/pubmed/29564497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3562-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|